Chanez P, Mann C, Bousquet J, Chabrier P E, Godard P, Braquet P, Michel F B
Clinique des Maladies Respiratoires, Hôpital de l'Aiguelongue, Montpellier, France.
J Allergy Clin Immunol. 1990 Sep;86(3 Pt 1):321-4. doi: 10.1016/s0091-6749(05)80094-6.
The bronchodilating effects of atrial natriuretic factor (ANF) were compared to effects of salbutamol in a double-blind, placebo-controlled, crossover study in eight subjects with asthma and with airflow limitation. ANF was infused intravenously (0.1 microgram/kg/min during 30 minutes) and caused a short-lasting significant (p less than 0.012) bronchodilation in all patients similar in intensity to intravenous salbutamol (0.13 microgram/kg/min). The duration of the effect of the beta 2-agonist, however, was longer. No severe side effects were noted with ANF infusion. ANF may play a role in the modulation of the bronchial tone in humans, but its usefulness in the treatment of asthma remains to be determined.
在一项针对八名患有哮喘且存在气流受限的受试者的双盲、安慰剂对照、交叉研究中，比较了心房利钠因子（ANF）与沙丁胺醇的支气管扩张作用。静脉输注ANF（30分钟内0.1微克/千克/分钟），所有患者均出现了短暂的显著支气管扩张（p<0.012），其强度与静脉输注沙丁胺醇（0.13微克/千克/分钟）相似。然而，β2激动剂的作用持续时间更长。输注ANF未观察到严重副作用。ANF可能在调节人类支气管张力中发挥作用，但其在哮喘治疗中的效用仍有待确定。
